Risultati di ricerca
Scientists at Tohoku University have discovered a novel approach that improves the efficacy of immune checkpoint blockade (ICB) - a novel form of cancer treatment utilizing immune checkpoint inhibitors (ICIs) - and minimizes the associated side effects.
- Promising Development for Breast Cancer Patients - tohoku.ac.jp
Promising Development for Breast Cancer Patients....
- Promising Development for Breast Cancer Patients - tohoku.ac.jp
1 apr 2024 · Objective: To inform the choice of first-line drugs in clinical practice and assess the safety and efficacy of ICI-chemotherapy combination treatment in older adult patients with previously untreated advanced NSCLC. Design, setting, and participants: This retrospective cohort study included 58 centers in Japan.
You can be engaged in discovering critical cells, cell signaling and genetic pathways relevant to Tumor Immunity development and function, investigating human and murine cancers or studying immune–mediated processes in tumor-microenvironment development, inflammation and oncogenesis.
Immunotherapy is considered one of the most important therapeutic strategies for patients with lung adenocarcinoma after the development of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance.
- Sachiko Kawana, Ryoko Saito, Yasuhiro Miki, Yuichiro Kimura, Jiro Abe, Ikuro Sato, Mareyuki Endo, Sh...
- 2021
Development of immune cell delivery system using biodegradable injectable polymers for cancer immunotherapy — Tohoku University. Yuta Yoshizaki, Kenta Horii, Nobuo Murase, Akinori Kuzuya, Yuichi Ohya. PHA - Molecular Pharmaceutical Science. Kansai University. Research output: Contribution to journal › Article › peer-review. Overview. Fingerprint.
Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer — Tohoku University.
